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ABSTRACT: The Mitochondrial Human Proteome Project aims at under-
standing the function of the mitochondrial proteome and its crosstalk with
the proteome of other organelles. Being able to choose a suitable and vali-
dated enrichment protocol of functional mitochondria, based on the speciﬁc
needs of the downstream proteomics analysis, would greatly help the
researchers in the ﬁeld. Mitochondrial fractions from ten model cell lines
were prepared using three enrichment protocols and analyzed on seven
diﬀerent LC−MS/MS platforms. All data were processed using neXtProt
as reference database. The data are available for the Human Proteome
Project purposes through the ProteomeXchange Consortium with the iden-
tiﬁer PXD007053. The processed data sets were analyzed using a suite of
R routines to perform a statistical analysis and to retrieve subcellular and submitochondrial localizations. Although the overall
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■ INTRODUCTION
The Mitochondrial Human Proteome Project (mt-HPP) is a
Human Proteome Organization (HUPO) initiative, led by the
Italian Proteomics Association (ItPA), focused on human mito-
chondrial proteins.1 Because of the intrinsic nature of the mito-
chondrial proteome, this action is part of both the Chromosome-
centric Human Proteome Project (C-HPP) and the Biology/
Disease Human Proteome Project (B/D-HPP). Themain goal of
this eﬀort is to obtain robust information about the integrative
role of proteins acting at the mitochondrial level, considering
both those encoded by the mitochondrial DNA (mt-DNA) and
by the nuclear DNA.
Mitochondria are very versatile organelles, and they are involved
in a plethora of cellular functions such as energy production,
regulation of death pathways, and calcium buﬀering.2 Therefore,
their dysfunction has been related to many pathological condi-
tions ranging from neurodegenerative disorders to cancer and
metabolic diseases.3−5 Hence, their dynamic proteome is parti-
cularly important in deﬁning their healthy state, the dynamics of
themitochondrial network, and, in turn, the cellular conditions.6−8
The detection of proteins associated with mitochondria in speci-
ﬁc physiological or pathological conditions is the main goal of
several research groups and proteomics is the most eﬀective
approach to achieve this outcome. Nevertheless, the enrichment
of mitochondria in the sample is needed to increase protein
identiﬁcation and quantiﬁcation. The lack of reproducibility
of many enrichment protocols, that leads to the introduction of
uncontrolled bias in the manipulated specimen, is well-known
and clearly detrimental for any subsequent analysis. It is not rare
to ﬁnd mitochondrial proteomics data reporting a low number
of Matrix proteins. This is mainly due to the mitochondrial
breakage along the enrichment procedure, with consequent
leakage of matrix-mitochondrial proteins into the cytosol and
the subsequent formation of membrane-surrounded artifacts,
containing proteins originally not present in the organelle.
In some cases, proteins associatedwithmitochondria, which deﬁne
their interaction with the endoplasmic reticulum or with the
autophagosome, are the most interesting ones. It is therefore
fundamental to deﬁne the best protocol capable of preserving
those interactions. Conversely, a diﬀerent protocol could be best
suited for studies requiring a deeper puriﬁcation of the samples.
It is well-known that the composition of mitochondrial proteome
is tissue related and, hence, the best protocol depends on both
the selected cellular model and the desired yield/purity.
For the above-mentioned reasons, a standardization eﬀort
aimed at deﬁning the most appropriate extraction method for
each cellular model in relation to a speciﬁc biological question
is necessary. The Italian consortium working on this project
includes 17 groups from 10 Universities and eight Research and
Care Centers. Ten cell lines representative of diﬀerent organs
and tissues were selected (BJ, NCI-H28, Hek293, HeLa, HepG2,
HUVEC, MDA-MB-231, THP1, U2OS, SH-SY5Y). They are all
standard cell lines widely used for basic research; they are deeply
characterized and, most importantly, are included in the panel
used for the mapping of Cell Atlas subcellular locations within
the Human Protein Atlas project.9 Some of them are also suitable
cell models for particular pathological conditions related to the
impairment of mitochondrial function.
Mitochondria were isolated with three diﬀerent methods
(diﬀerential centrifugation, sucrose gradient separation, a commer-
cial kit based on surfactants). To collect homogeneous data, the
samples prepared with diﬀerent methods from the same cell line
were analyzed by the same mass spectrometry (MS) laboratory.
The yield and the purity of each enrichment were assessed by
Western blot, before MS analysis. Moreover, integrity of some
mitochondrial preparations was checked by measuring the oxygen
consumption rate and the citrate synthase activity. Data elab-
oration with the commercial software PEAKS Studio 7.5 was
centralized in one laboratory. Data sets were analyzed by an auto-
mated procedure, providing the coverage of subcellular and sub-
mitochondrial locations. Eventually, the identiﬁed proteins were
mapped on a mitochondrial functional proteome network10 to
verify the proportion of proteins associated with mitochondria.
■ EXPERIMENTAL PROCEDURES
Cell Lines
All the cell lines used (BJ, SH-SY5Y, U2OS, MDA-MB-231,
NCI-H28,Hek293,HUVEC, THP1,HepG2,HeLa) are of human
origin. Neuroblastoma SH-SY5Y (ECACC 94030304; Lot No.
11C016), osteosarcoma U2OS (ATCC HTB-96), skin ﬁbro-
blast BJ (ATCC CRL-2522), embryo kidney Hek293 (ATCC
CRL-1573), cervix adenocarcinoma Hela (ATCC CCL-2),
hepatocellular carcinoma HepG2 (ATCCHB-8065), breast cancer
derived MDA-MB-231 (ATCC HTB-26), normal umbilical
vein HUVEC (ATCC PCS-100−010), lung metastasis derived
NCI-H28 (ATCC CRL-5820), and acute monocytic leukemia
THP1 (ECACC 88081201, Lot No. 14J009) cells were main-
tained at 37 °C under humidiﬁed conditions and 5%CO2 and were
grown in the appropriate medium, as detailed in Table S-1. Cell
culture media and other reagents were from Euroclone, Sigma,
Corning, and Gibco Life Technologies. Absence of mycoplasma
was periodically checked by EZ-PCR Mycoplasma Test Kit
(Biological Industries) according to manufacturer’s instructions.
Mitochondrial Enrichment
Mitochondria were isolated from 107−108 cells, depending on
the cell type. The number of cells and the lysis buﬀer volume
used for each cell type are reported in Table S-1.
Diﬀerential Centrifugation. Cells were detached (if adher-
ent) with trypsin (0.05%)-EDTA (0.02%), collected by centri-
fugation (300 × g, 25 °C, 7 min), and then resuspended in isola-
tion buﬀer (250 mM sucrose, 10 mMTris/MOPS pH 7.4, 1 mM
EGTA, 10% v/v protease inhibitor mix, P8340 Sigma-Aldrich).
Cells were mechanically lysed with a glass/glass Dounce homog-
enizer, on ice, using a number of strokes optimized for each cell
line. Homogenates were centrifuged (600 × g, 4 °C, 10 min) and
the supernatants collected and further centrifuged (7000 × g,
4 °C, 10 min) to isolate the mitochondrial fractions.
number of identiﬁed total and mitochondrial proteins was not signiﬁcantly dependent on the enrichment protocol, speciﬁc line to
line diﬀerences were observed. Moreover, the protein lists were mapped to a network representing the functional mitochondrial
proteome, encompassing mitochondrial proteins and their ﬁrst interactors. More than 80% of the identiﬁed proteins resulted in
nodes of this network but with a diﬀerent ability in coisolating mitochondria-associated structures for each enrichment protocol/cell
line pair.
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Sucrose Gradient Separation. Cells were washed with
1 mM EDTA in PBS and, if adherent, detached with Trypsin
(0.05%)-EDTA (0.02%). Cells were collected by centrifugation
(600 × g, 25 °C, 10 min) and then resuspended in mitochondrial
buﬀer (MB: 210 mM D-mannitol, 70 mM sucrose, 1 mM EDTA,
10 mM Hepes, pH 7.5 plus 1X Protease Inhibitor Cocktail,
P8340 Sigma-Aldrich). Lysis was performedmanually in a Teﬂon/
glass homogenizer in ice. Homogenization was repeated three
times, each time with a number of strokes optimized for diﬀer-
ent cell lines (Hek293, 3 × 30 strokes; U2OS, 1 × 50, 2 × 40;
HeLa, 3 × 30; SH-SY5Y, 3 × 50; NCI-H28, 1 × 30, 2 × 20;
MDA-MB231, 3 × 40; THP-1, 3 × 50; 1, 3 × 30 HUVEC).
Homogenates were centrifuged (600 × g, 4 °C, 10 min) and
supernatants collected, pooled together, and further centrifuged
(7000 × g, at 4 °C, 10 min) to collect the crude mitochondria
fractions. The crude mitochondria pellets were suspended in
250 μL of MB and layered on a discontinuous sucrose gradient
(1.6M/1.2M sucrose in 10mMHepes, 1 mMEDTA, 0.1% BSA,
at pH 7.5). The sucrose gradient was ultracentrifuged (96 000× g,
4 °C, 2 h)with acceleration and deceleration set to 3, in a Beckman
Ultracentrifuge equipped with a SW40Ti rotor in ultraclear tube
(Beckman). Upon ultracentrifugation, visible as a whitish band
at the gradient interface, mitochondria were collected with an
insulin syringe, washed by dilution in four volumes of MB, and
collected by centrifugation (13 000 × g, 4 °C, 10 min).
Commercial Kit Based on Surfactants. Cells were
detached with trypsin (0.05%)-EDTA (0.02%) (if adherent)
and collected by centrifugation. Mitochondria were isolated using
the Mitochondrial Isolation Kit MITOISO2 (Sigma-Aldrich),
following the detergent lysis protocol of the manufacturer.
Brieﬂy, after two washes in PBS, cells were lysed in lysis buﬀer
with protease inhibitor cocktail (P8340 Sigma-Aldrich). Cells
were then incubated for 5 min on ice before adding two volumes
of extraction buﬀer and centrifuging (600 × g, 4 °C, 10 min).
The supernatant was transferred in a fresh tube and centrifuged
(11 000 × g, 4 °C, 10 min) to obtain a pellet containing the
mitochondria. The pellet was further washed with the extrac-
tion buﬀer to remove contaminants. For BJ and MDA-MB-231
cells only, the supernatant obtained after the ﬁrst centrifuga-
tion was discarded to proceed to a second lysis of the cellular
pellet with lysis buﬀer. A second centrifugation (600 × g, 4 °C,
10 min) was performed after adding two volumes of extraction
buﬀer.
After mitochondria enrichment, dry pellets from three inde-
pendent preparations for each condition were stored at −80 °C
before MS andWestern Blot analysis or directly used to measure
the oxygen consumption rate.
Western Blot
Proteins were extracted from cells or subcellular-enriched pellets
using radioimmunoprecipitation assay (RIPA) buﬀer (50 mM
Tris-HCl pH 7.6, 150 mM NaCl, 1% sodium deoxycholate, 1%
NP-40 and 0.1% SDS). Lysates were centrifuged (15 000 × g,
4 °C, 30 min), and the supernatant was collected. Equal amount
of proteins were incubated in Laemmli loading buﬀer, resolved in
10% or 13% SDS-gels and transferred to polyvinylidenediﬂuoride
(PVDF)membranes (Millipore Corporation, Bedford, MA, USA)
at 1.0 mA/cm2, 1.5 h. PVDF membranes were saturated in
tris-buﬀered saline with 0.05% Tween 20 (TBS-T) containing
5% dried skim milk. Blots were probed with antibodies against
a nuclear marker (Histone H3, Sigma-Aldrich H0164, 1:2500),
an outer mitochondrial membrane marker (Voltage-dependent
anion channel 1 - VDAC1, Abcam ab15895, 1:1000), an inner
mitochondrial membrane marker (cytochrome c oxidase sub-
unit 5B - COX5β, Sigma-Aldrich HPA034517, 1:1000), a mito-
chondrial matrix marker (citrate synthase - CS, Sigma-Aldrich
AMAb91006, 1:1000), and a cytosolic marker (β-tubulin,
Thermo Scientiﬁc, MA5−16308, 1:8000). Blots were incubated
with proper peroxidase-conjugated secondary antibodies, that is,
antirabbit (Millipore Corporation AP132P, 1:1500) and antimouse
(Millipore Corporation 12−349, 1:3000) in 5% milk-TBS-T.
Enhanced chemiluminescence substrate (Millipore Corporation)
was used to visualize the peroxidase signals. Images (16 bit gray-
scale) were acquired using the G:BOXChemi XT4 (Syngene,
Cambridge, UK) system.
Mitochondrial Proteins Extraction and in-Solution
Digestion
To perform shotgun MS analysis of mitochondrial proteins,
all the samples were lysed and digested in RapiGest Solution
(RG, Waters Corporation): each mitochondrial pellet was resus-
pended in 50 μL of RG 0.1% in 50 mM ammonium bicarbonate
and incubated on ice for 30 min. Protein content was quantiﬁed
using the Bradford protein assay (BIO-RAD). Before the diges-
tion, proteins were reduced with 1 mM TCEP, at 55 °C for
30 min and alkylated in the presence of 20 mM iodoacetamide
for 30 min in the dark, at RT.
Porcine Trypsin (Promega) was added at 50:1 protein to
enzyme ratio and digestion ran overnight at 37 °C. Acidiﬁcation
with 0.5% TFA blocked the digestion reaction and, upon incu-
bation at 37 °C for 30 min, led to RG hydrolysis. The peptides
were recovered by centrifugation at 15 000× g for 10 min at 4 °C
and then loaded directly on the respective chromatographic
system for the MS analysis.
Liquid Chromatography and Mass Spectrometry Analysis
(LC−MS/MS)
Mitochondrial peptides were analyzed using several MS platforms
and chromatographic conditions (see Table 1) running a technical
duplicate per sample. Details on all the instrumental setup used
for the acquisition are provided as Supporting Information.
Data Analysis
Raw data were processed using PEAKS Studio 7.5 (Bioinfor-
matics Solutions Inc., Waterloo, ON Canada) and searched
against neXtProt (July 2017; 42 151 total entries). Parent and
Fragments Mass Error Tolerance were set according to the
instrument or acquisition type and ranged from 10−40 ppm for
precursors and from 0.05−0.6 Da for fragments. Other search
parameters were trypsin enzyme speciﬁcity, twomissed cleavages
Table 1. MS and Chromatographic Platforms
no. LC system column
mass
spectrometer cells
1 nanoAcquityM
Class
Waters HSST3 C18 75 μm ×
15 cm
Synapt G2 Si BJ, HeLa
2 Dionex Ulti-
Mate 3000
Thermo Easy-Spray PepMap
RSLC C18 75 μm × 50 cm
Orbitrap Fu-
sion
Hek293
3 Dionex Ulti-
Mate 3000
MS Wil GmbH C18 75 μm ×
20 cm
LTQ-Orbi-
trap- Velos
MDA-
MB231,
THP1
4 nanoEASY II Nanoseparations C18 100 μm
× 20 cm
LTQ-Orbi-
trap-XL
NCI-H28
5 Dionex Ulti-
Mate 3000
Thermo Easy-Spray PepMap
RSLC C18 75 μm × 50 cm
Bruker Im-
pact HD
HUVEC
6 Ekspert
nanoLC 400
Thermo Acclaim PepMap
100 75 μm × 25 cm
TripleTOF
5600+
HepG2
7 nanoEASY II Thermo Acclaim PepMap
100 75 μm × 25 cm
Bruker maXis
HD
SH-SY5Y,
U2OS
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per peptide, one nonspeciﬁc cleavage, ﬁxed carbamidomethylation
of cysteines and variable oxidation of methionines, deamidation
of glutamine and asparagine (NQ), with two variable PTM per
peptide. FDR threshold on PSMs was set to 0.1%, typically
resulting in FDR on peptides and proteins lower than 0.2%.
In view of concatenating numerous data sets from several biological
samples, very stringent FDR ﬁltering conditions were chosen.
Protein identiﬁcation tables for each biological replicate were
analyzed using R (version 3.3.2),11 using the package UniProt.ws12
in the Bioconductor program.13The complete code used is enclosed
in the Supporting Information. Brieﬂy, 63 tables (three biological
replicates, two enrichment methods for nine cell lines, three
enrichment methods for SH-SY5Y cells) in comma separated
values format were read, and UniProtKB accession numbers and
gene symbols were extracted. Proteins observed in a single bio-
logical replicate were discarded. Proteins were ranked by retain-
ing all protein identiﬁcations whose computed score (−10Logp/
MW) was higher than a threshold value equal to 5.0 × 10−4 with
respect to the cumulative score14 (i.e., the sum of all scores for a
sample). The number of ﬁltered identiﬁcations was exported
for each replicate. Gene symbols were then searched in
MitoCarta2.015 and Integrated Mitochondrial Protein Index
(IMPI Q2 2016)16 databases to obtain the number of entries
annotated as mitochondrial in each biological replicate. Primary
subcellular location category was also extracted from UniProt
annotation (release 2017_07) to identify principal sources of
contamination. Identities annotated as mitochondrial as the
primary subcellular location were further classiﬁed as OMM
(outer mitochondrial membrane), IMS (intermembrane space),
IMM (inner mitochondrial membrane), Matrix, or NC (not
classiﬁed). The same proportions were calculated in the neXtProt
database. The Fisher’s exact test was performed to compare results.
To evaluate if the number of identiﬁcations for the same cell
line with diﬀerent mitochondrial enrichment procedures was
signiﬁcantly diﬀerent, a multiple t test was performed on the
number of total and mitochondrial identiﬁed proteins in each
biological replicate. To compare the results of the three enrich-
ment methods used for the SH-SY5Y cell line, one-way ANOVA
was performed. The Tukey’s posthoc test was used to identify
signiﬁcant multiple comparisons. In both cases, a p value <0.05
was considered signiﬁcant. Diﬀerences in the percentage of protein
identities in the four most represented primary subcellular location
categories were evaluated by the nonparametric Kruskal−Wallis
test followed by the posthoc Dunn test.
Network Analysis
Consensus lists were mapped on the reference network for the
functional mitochondrial proteome,10 a network composed of
6592 nodes (1361 of them labeled as “mitochondrial” in the
neXtProt database and 5231 “mitochondrial associated”
interactors in the IMEX consortium) and 16 350 edges. Mapped
nodes were extracted and visualized to obtain the number of
“mitochondrial” and “mitochondrial associated” proteins for each
cell line and enrichment method. The analysis was performed
using Cytoscape (v3.4.0).17
■ RESULTS
Samples Characterization Previous to MS Analysis
To verify the enrichment yield and to conﬁrm low levels of
cytosolic and nuclear contaminations, all the specimens were ﬁrst
assessed by Western blots. A representative Western blot of the
diﬀerently enriched mitochondrial proteins from SH-SY5Y cells
is reported in Figure 1. Beta-tubulin was used as cytosolic marker,
citrate synthase (CS) as mitochondrial Matrix marker, VDAC1
as OMM marker, cytochrome c oxidase 5B (COX5β) as IMM
marker, and Histone H3 (H3) as nuclear marker. Figure 1 shows
that mitochondrial fractions (M) are enriched in markers from
the three mitochondria compartment (Matrix, OMM, and IMM),
cytosolic contamination is very low with respect to the total
fraction (T) and nuclear contamination is acceptable, if H3 levels
are compared with those of the nuclear fraction (N). Comparable
enrichment results were obtained for the threemethods.Western
blots of preparations from all the other cell lines are reported
in Figure S-1. Mitochondria from selected cell lines were also
functionally tested in terms of integrity (citrate synthase assay)
and respiration (oximetry or microscale oxygraphy), as shown in
Figure S-2.
Shotgun Proteomics Analysis of the Mitochondrial
Proteome
The shotgun analysis was performed on the proteins extracted
frommitochondrial fractions obtained by two diﬀerent enrichment
protocols on each cell line. All three enrichment protocols were
employed on the reference SH-SY5Y cells only. The complete
Figure 1. Mitochondrial samples yield and purity check. SH-SY5Y mitochondrial enriched fraction obtained by diﬀerential centrifugation, the
commercial kit based on surfactants and the sucrose gradient protocol. N = nuclear fraction; M = mitochondrial fraction; T = total fraction.
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study design is presented in Figure 2A. This study was planned to
ensure a statistically signiﬁcant number of enrichment replicates
for each method and, at the same time, a suﬃcient randomization
so that the origin of the samples and the laboratory perform-
ing the isolation were independent. Moreover, to map the
large heterogeneity of diﬀerent LC−MS/MS platforms within
the proteomics community, we employed seven diﬀerent
nanoanalytical MS setup, using the same platform for prepara-
tions from the same cell line.
Shotgun data from all the laboratories of the Consortium
were processed using PEAKS Studio 7.5 as described in the
Experimental Procedures section. The raw data were deposited
to the ProteomeXchange Consortium via MassIVE repository
with the data set identiﬁers PXD007053 and MSV000081329
Figure 2. Study design of the mt-HPP consortium standardization action. (A) Workﬂow from left to right describes the steps of the project in
chronological order: the preparation of cell lines with standard procedures, the mitochondrial enrichment with the methods reported, the LC−MS/MS
analysis (for details, see Table 1), and the ﬁnal data analysis. (B) Flowchart describes the three independent routines for the data analysis: the ﬁrst one
(blue) reads the 63 data tables and parses cell lines, mitochondrial enrichment methods, signiﬁcance scores, Uniprot IDs, and gene symbols; the second
one (green) reads the summary tables and maps the IDs observed in each biological replicate against MitoCarta2.0 and IMPI; the third (red) reads the
consensus lists and maps their subcellular and submitochondrial locations (codes are reported in the Supporting Information).
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and are freely available for download. The 63 data sets were
analyzed using the automated procedure described in Figure 2B
and enclosed in the Supporting Information. Brieﬂy, protein lists
were ﬁltered by eliminating proteins that were observed in
a single preparation and thresholded by retaining all protein
identiﬁcations whose ranking coeﬃcient (−10Log p/MW) was
higher than a threshold value equal to 5.0 × 10−4 with respect to
the sum of all coeﬃcients of the identiﬁed proteins in a single
experiment. Considering this threshold, the number of identiﬁed
proteins varied between 200 and 800, depending on the cell line,
the enrichment procedure used, and, in part, the LC−MS/MS
technical setup. For some cell lines (NCI-H28, HUVEC, MDA-
MB-231, THP1), the number of protein identities was signiﬁ-
cantly dependent on the enrichment procedure (Figure 3A).
SH-SY5Y cells were used as reference model to compare the
three mitochondrial enrichment protocols by shotgun analysis
(Figure 3B).
The automated procedure allowed the annotation of protein
lists using MitoCarta2.0 and IMPI Q2 2016. Protein IDs were
considered as mitochondrial if deﬁned as such in at least one
of the two databases. On average, the fraction of proteins
identiﬁed as mitochondrial resulted similar for the three
methods (diﬀerential centrifugation: 46% ± 11%; sucrose
gradient 54% ± 10%; kit based on surfactants 52% ± 11),
although diﬀerences at the single cell line level were observed
(Figure 3C,D).
Evaluation of the Performance of the Mitochondrial
Enrichment Protocols
To evaluate the performances of the mitochondrial enrichment
procedures, protein IDs were classiﬁed using the UniProt
“primary subcellular location” category (by grouping information
as reported in the Supporting Information). Then data were
sorted by the enrichment method. The topmost represented
categories for all the methods were “Mitochondrion”,
“Cytoplasm”, “Nucleus”, and “ER”, respectively, as reported in
Figure 4A. In general, the percentage of mitochondrial proteins
is not statistically diﬀerent among the methods, whereas the
enrichment of cytoplasmic and nuclear proteins appears
signiﬁcantly diﬀerent for the three protocols herein considered.
The proteins annotated as mitochondrial were further
analyzed to compare their submitochondrial localization in the
OMM, the IMS, the IMM, and the mitochondrial Matrix. The
results reported in Figure 4B indicate that there is no signiﬁcant
diﬀerence among the enrichment methods.
In our data sets, the percentages of mitochondrial proteins in
each compartment were 9.0% OMM, 5.2% IMS, 40.5% IMM,
and 18.5% Matrix. These numbers are comparable to what was
obtained from the same analysis performed on the neXtProt
database (9.4%OMM, 4.9% IMS, 29% IMM, and 15.7%Matrix),
with the exception of a higher representation of IMM proteins in
our samples. However, the Fisher’s exact test revealed no signiﬁ-
cant diﬀerence between our percentages and those expected from
Figure 3.Number of total and mitochondrial proteins identiﬁed for each cell line. (A) Total number of proteins identiﬁed for each cell line/enrichment
method pair (after thresholding as explained in the text). (B) Total number of proteins identiﬁed for each of the three mitochondria enrichment method
in SH-SY5Y cells (after thresholding as explained in the text). (C) Proportion of mitochondrial proteins for each cell line/enrichment method pair.
(D) Percentage of mitochondrial proteins identiﬁed for each of the three mitochondria enrichment method in SH-SY5Y cells. Proteins were considered
as “mitochondrial” if classiﬁed as such in either MitoCarta2.0 or IMPI. Bars represent mean ± SEM; ∗p < 0.05, ∗∗p < 0.001.
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the database. Therefore, we can state that the three methods do
not under- or over-represent submitochondrial components.
Mapping on the Reference Network
The proteins observed in at least two out of three biological
replicates for each preparation were mapped on the reference
network of the functional mitochondrial proteome.10 This proce-
dure allowed us to identify together with themitochondrial proteins
also the proteins that are physically or functionally associated
with mitochondria, thus highlighting the ability of each enrich-
ment method to obtain diﬀerent amounts of proteins that are not
strictly mitochondrial, but related to this organelle. Figure 5
reports the mapped proteins for the three protocols on the
SH-SY5Y cells. Maps for all the other preparations are reported
in the Supporting Information.
Maps were analyzed to extract the total number of mapped
proteins, the number of mitochondrial proteins (neXtProt sub-
cellular location) among them, the number of proteins mapping
to the largest cluster, and the number of mitochondrial proteins
(neXtProt subcellular location) in the cluster. Results are shown
in terms of percentage in Table 2.
■ DISCUSSION
Mitochondrial dysfunction is widely implicated in the origin
and development of various age-associated diseases includ-
ing metabolic syndromes, cardiovascular diseases, cancer, and
neurodegenerative disorders. Bioenergetics aspects linked to
mitochondria activity in human disease have provided new
opportunities for diagnosis, therapy, prevention, and in connec-
ting various domains of medicine.18 Dysfunctions can be assessed
in isolated mitochondria. Assays of the amounts or activities
of speciﬁc complexes and enzymes, mitochondrial morphology,
and responses to speciﬁc stressors can be useful to test speciﬁc
hypotheses, but should generally be held in reserve and not used
as the primary assay for mitochondrial dysfunction. A more
indirect indication of mitochondrial dysfunction is raised by the
pattern of changes in gene arrays, proteomics, or metabolomics,
where gene ontology categories may suggest alterations in energy
metabolism or in other cellular functions where mitochondria
play a pivotal role (e.g., apoptosis, calcium homeostasis).
Over the past 20 years, interest in the ﬁeld of mitochondria
proteomics research has increased dramatically. The experimental
strategy for deﬁning the mitochondrial proteome is delineated by
the application of mass spectrometry to identify proteins from
highly enriched mitochondrial extracts. With the improvement
in mitochondria puriﬁcation strategies, together with MS-based
proteomics with higher sensitivity and mass accuracy, mitochon-
drial proﬁling could represent a powerful technique in studying
disease states. However, methods to assess the potential impact
of mitochondria puriﬁcation protocols have been limited. More-
over, mitochondrial proteome in any cell line is delineated by a
combination of nuclear chromosomes and mitochondrial
Figure 4. Percentage of four top subcellular locations for each mitochondrial enrichment protocol. (A) Proportion of mitochondrial, cytoplasmic,
nuclear, and endoplasmic proteins for each enrichment method (UniProt primary subcellular location). Statistical signiﬁcance was evaluated with the
Kruskal−Wallis test, followed by Dunn’s posthoc test. ∗p < 0.05. (B) Submitochondrial location, expressed as a percentage of mitochondrial proteins in
the OMM, the IMS, on the IMM, or in the mitochondrial Matrix. NC: not classiﬁed. Bars represent mean ± SEM.
Figure 5.Mapping of the proteins identiﬁed from SH-SY5Y cells on the functional mitochondrial reference network. Protein IDs (observed in at least
two out of three biological replicates and with a (−10Log p/MW) > 5.0× 10−4) were mapped on the reference network of the functional mitochondrial
proteome. Cyan nodes represent mitochondrial proteins as annotated in neXtProt, whereas red nodes are their ﬁrst interactors.10 Proportion of IDs are
reported in Table 2.
Journal of Proteome Research Article
DOI: 10.1021/acs.jproteome.7b00350
J. Proteome Res. XXXX, XXX, XXX−XXX
G
chromosome-coded proteins, together with their interacting
structures. Given these requirements and constraints, it is hardly
surprising that a relatively small number of largely complete and
robustly validatedmitochondrial proteomes were reported so far.
In this work, we assessed the performances of three diﬀerent
puriﬁcation methods on ten human cell lines of diﬀerent origin.
The human cell lines were selected because they are some of the
most thoroughly characterized cell lines in biomedical research9
(i.e., HeLa, Hek293, U2OS) or because they are commonly used
cellular models for speciﬁc conditions. Many of them are included
in the panel used for the mapping of Cell Atlas subcellular
locations within the Human Protein Atlas project.9 Moreover,
they include normal noncancer cells such as umbilical endothelial
cells (HUVEC) and skin ﬁbroblasts (BJ). BJ human ﬁbroblast
cells were one of the ﬁrst cell types to be reprogrammed into
induced pluripotent stem (iPS) cells and are commonly used
in human cell reprogramming studies.19 Moreover, the use of
ﬁbroblasts is emerging in diﬀerent research ﬁelds. Since they are
relatively easy to obtain from patients skin biopsy, they provide a
unique cell system for personalized medicine.20−22 SH-SY5Y are
widely used in neuroscience research as a neuron-like model easy
to grow and maintain indeﬁnitely.23−27 MDA-MB-231 are one of
the most frequently used cell lines for in vitro experimental study
of the hormone-independent breast cancer. The mitochondrial
respiration defects observed in MDA-MB-231 cells were
demonstrated to be caused by mutations in mtDNA, which
in turn is responsible for the high metastatic potential.28−30
NCI-H28 is a malignant mesothelioma cell line, normally used to
investigate this pathological condition.31 Endothelial cells (ECs),
such as HUVEC, are suitable for the study of endothelial physio-
logy, vascular functions, and interaction of ECs with blood cells
and various mediators, all of which are relevant in diﬀerent dis-
eases, such as atherosclerosis, inﬂammation, and immunity.32 THP1
is a human leukemia monocytic cell line, which can be easily
diﬀerentiated into a macrophage phenotype, and hence, it has
been extensively used to study monocyte/macrophage func-
tions.33,34 HepG2 cell line, which was derived from a liver hepa-
tocellular carcinoma, is a good cellular model to isolate mito-
chondria, to perform measurements of mitochondrial respiration,
to identify drug-induced mitochondrial toxicity, and to evaluate
the role of mitochondrial dysfunction in cancer progression.35−37
Far to be representative of all the cellular models used in mito-
chondrial research, our cell panel should be considered as a
starting working hypothesis to improve mitochondrial enrich-
ment for proteomics studies.
The puriﬁcationmethods consisted of an isolation kit based on
a surfactant cell lysis, diﬀerential centrifugation, and sucrose
gradient separation, based on mechanical homogenization in a
nonionic osmotic solution, where sugars are used as osmolytes.
First, we assessed purity and yield of the enriched fractions by
Western blot. Nevertheless, this simple assay may not be suﬃ-
cient to validate each fraction undergoing LC−MS/MS. Actually,
long mitochondrial chains may break out during isolation, thus
leading to loss of Matrix proteins. Similarly, the mechanical stress
during the extraction procedure may improve the formation of
mitoplasts, where OMMand IMS proteins are underrepresented.
Therefore, we assessed mitochondria integrity by measuring
the citrate synthase activity and the oxygen consumption rate
of enriched mitochondria in the most problematic samples.
The results indicated that mitochondrial integrity is retained
and it is independent of yield and purity. Moreover, we veriﬁed
a posteriori the submitochondrial location of mitochondrial
proteins according to UniProt annotation. Their relative propor-
tion is in agreement with that of the neXtProt database, revealing
that the proteomics analysis was performed on intactmitochondria.
Three biological replicates for each mitochondria enrichment
protocol were prepared and analyzed separately in technical
duplicate by shotgun proteomics. This is a strong constrain
Table 2. Mapping on the Functional Mitochondrial Proteomea
cell line method % mapped % mitochondrial % clustered % mitoclustered
BJ kit 77 36 22 53
diﬀ. centr. 84 21 30 43
NCI-H28 kit 84 46 29 56
gradient 88 38 28 65
Hek293 diﬀ. centr. 87 44 41 58
gradient 84 63 38 70
HeLa kit 82 46 29 70
gradient 86 41 34 56
HepG2 diﬀ. centr 81 57 32 69
kit 78 38 25 65
HUVEC kit 79 38 33 56
gradient 82 30 37 49
MDA-MB-231 diﬀ. centr. 79 32 38 49
kit 76 36 36 53
THP1 kit 76 63 36 72
gradient 78 51 38 62
U2OS diﬀ. centr. 83 30 29 53
gradient 87 45 30 66
SH-SY5Y diﬀ. centr. 89 33 28 54
kit 90 60 26 66
gradient 89 47 32 64
aNotes: diﬀ. centr, diﬀerential centrifugation; gradient, sucrose gradient; % mapped, percentage of protein IDs mapped on the reference network
(mapped/total IDs); % mitochondrial, percentage of mapped IDs annotated as mitochondrial in neXtProt (mitochondrial/mapped); % clustered,
percentage of mapped IDs that cluster in the main subnetwork (clustered/mapped); % mitoclustered, percentage of clustered IDs annotated as
mitochondrial in neXtProt (mitochondrial/clustered).
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to ensure that shotgun data are biologically representative and
meaningful.38 Indeed, the observation of a single pooled sample,
in the absence of biological replicates, may lead to neglecting the
intrinsic variability of specimens. For this reason, only proteins
observed in at least two out of the three biological replicates were
taken into account.
The study design was developed to highlight diﬀerences in the
enrichment protocols, which are independent of the analytical
set up of the LC−MS/MS systems. Thus, we employed a variety
of diﬀerent LC−MS/MS platforms, however maintaining the
same set up within the same cell line. Another important issue
to be faced is the number of identiﬁcations that diﬀerent
chromatographic systems coupled to diﬀerent mass spectrom-
eters may provide. It is straightforward that lists of diﬀerent
lengths representing similar samples will share the identities of
most abundant proteins. We tackled this issue by analyzing
samples isolated with diﬀerent methods from the same cell line
using the same instrument. Additionally, we ranked identiﬁed
proteins in terms of the signiﬁcance score over the molecular
weight, a concept close to the Exponentially Modiﬁed Protein
Abundance Index (emPAI).14 Signiﬁcance (−10Log p) scores
reﬂect peptide-spectrum and protein-peptide matches and the
molecular weight reﬂects the length of the protein sequence.
After thresholding (i.e., retaining proteins with the rank score
higher than a threshold), the dimension of the lists was inde-
pendent of the instrumental platform. Noticeably, the thresh-
olding procedure was necessary only for comparison purposes of
the present work and does not strictly reﬂect a label-free quanti-
ﬁcation of the proteins. Analysis of the thresholded data revealed
no signiﬁcant diﬀerences in terms of number of identiﬁed
proteins among the three methods. Although with the limitation
represented by the use of two preparative methods in the other
cell lines, signiﬁcant discrepancies were observed for speciﬁc
cells. In particular, the diﬀerential centrifugation protocol was
better suited for MDA-MB-231, the sucrose gradient seemed
to work better than the kit for THP1 cells, whereas the number
of identiﬁed proteins was higher with the kit for NCI-H28,
HUVEC, and SH-SY5Y cells.
A ﬁrst approach to determine the performance of the enrich-
ment protocols in terms of mitochondrial proteins identiﬁed
in each experiment relied on reference databases such as
MitoCarta2.0 and IMPI Q2 2016. Merging the results for each
enrichment protocol, mitochondrial proteins always accounted
for about 50% and, consequently, diﬀerences associated with the
enrichment method were not signiﬁcant. However, a signiﬁcantly
higher enrichment was observed for HepG2 cells, where diﬀer-
ential centrifugation recovers more mitochondrial proteins than
the kit, and for Hek293 and U2OS cells, where sucrose gradient
works better than diﬀerential centrifugation. For BJ, NCI-H28,
HUVEC, THP1, and SH-SY5Y cells, the kit gives the best results.
Therefore, these ﬁndings should guide researchers through the
choice of the appropriate method for a given cell line. A second
analysis to evaluate the speciﬁcity of the enrichment procedures
was performed considering the primary subcellular location as
annotated in UniProt. This method is not sensitive, because
mitochondrial proteins may have a location other than mito-
chondrial as the primary annotation. However, one can retrieve a
general information about the occurrence of the four most
frequent primary locations. Results show that the kit allows for a
signiﬁcantly lower enrichment in cytoplasmic proteins, whereas
the gradient leads to the lower contamination by nuclear proteins.
One of the key points of the present study is the ability
to selectively coisolate other cell structures associated with
mitochondria. To this purpose, we cannot rely on “classical”
databases. Recently, we proposed the concept of the functional
mitochondrial proteome as a large (6592 nodes) network encom-
passing all the proteins labeled as mitochondrial in neXtProt
together with their ﬁrst interactors (IMEX consortium, 5231
nodes). Noticeably, mapping the protein lists on this network
allowed us to match more of 80% identities, thus showing that
nonmitochondrial proteins are indeed associated with mito-
chondria, from a functional point of view, and can be enriched
together with mitochondria. If we again consider SH-SY5Y cells
to compare three methods, we observe that 89 ± 1% iden-
tities are mapped on the reference network, whereas a variable
percentage of them is strictly mitochondrial, ranging from 33%
for the diﬀerential centrifugation protocol to 60% for the kit.
Thus, relative data in Table 2 should provide a background for
the choice of the preferred method, privileging purity of enriched
mitochondria or coenriching associated structures. Further
elements may arise from the analysis of the size of the main
cluster and of mitochondrial proteins within, showing the ability
to recover entire supramolecular complexes. This is particularly
important for proteins that dynamically interact with mitochon-
dria and exert a chronosteric eﬀect (e.g., parkin, which was never
identiﬁed in the present study).
In conclusion, we have compared suitable procedures to achieve
an eﬀective MS analysis of the mitochondrial proteome, deﬁning
the most advisible enrichment method for diﬀerent experimental
designs, irrespective of the analytical LC−MS/MS platform
employed. This standardization action will advisibly contribute
to future projects of the mt-HPP of the B/D-HPP and add
several mitochondrial data sets on ProteomeXchange to be used
as reference for future proteomics studies. We do not draw a
unique conclusion, as no method is preferable as such. We instead
provide some interesting hints for the diﬀerent cellular models
used. From a biological perspective, the investigation of the
mitochondrial proteome from an integrated, functional point of
view should improve the comprehensive vision of key signaling
pathways and biological processes converging onto the mitochon-
drion. Convergent signals are sensitive to the puriﬁcation methods
used, oﬀering the opportunity for increasing the knowledge of
biochemical and genetic aspects of mitochondrial biology and
pathology. Of particular interest will be the elucidation of mito-
chondria-nuclear crosstalks that regulate cell-speciﬁc features,39
which are themselves epigenetically determined.40
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